On August 25, 2022 Scandion Oncology (Scandion) reported its interim report for Q2 2022 (Press release, Scandion Oncology, AUG 25, 2022, View Source;interim-report-q2-2022,c3619895 [SID1234618643]). The following is taken from the report.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Bo Rode Hansen, President and CEO, comments
"The second quarter of 2022 saw us raise capital to fund our operations into 2024 and maintain momentum in our clinical trials as we continue to execute on our strategy to ensure long term value creation"
Key Figures & Highlights
On May 11, Scandion enhanced management and clinical development function with appointment of a new Chief Medical Officer. Dr. Alfredo Zurlo brings decades of experience from clinical development in oncology.
On May 25, Scandion announced that board member Thomas Feldthus will step down from the board of directors due to other professional commitments, having recently taken the position as CEO of Saniona.
On June 1, Scandion resolved on a Rights Issue. The issue is covered by subscription and guarantee commitments from principal owners and new investors corresponding to approximately 80% of the issue proceeds.
On June 15, Scandion published prospectus in connection with the rights issue
Highlights after the end of the period
On July 4, Scandion announced final outcome of its rights issue. Through the issue, Scandion raises approximately SEK 75 million before deduction of issue related costs.
On July 26, Scandion’s rights issue was registered with the Danish Business Authority.
On August 17, Scandion announced extension of the PANTAX trial due to better-than-expected tolerability of SCO-101.
On August 19, Scandion received approvals for next parts of the CORIST trial. The development of SCO-101 will continue as planned with expansion of the CORIST trial expected to commence during the third quarter of 2022.
The interim report Q2 2022 is available on the Company’s website: www.scandiononcology.com.
Audiocast today, August 25 at 10:00 am CET
Today at 10:00, Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update.
At the end of the presentation there will be a Q&A session.